Deans' stroke musings: Abstract P194: Artificial Intelligence-Powered Non-Invasive and Frequency-Tuned Electromagnetic Field Therapy Improves Upper Extremity Motor Function in Sub-Acute Stroke Patients: A Pilot Randomized Controlled Trial

Changing stroke rehab and research worldwide now.Time is Brain! trillions and trillions of neurons that DIE each day because there are NO effective hyperacute therapies besides tPA(only 12% effective). I have 523 posts on hyperacute therapy, enough for researchers to spend decades proving them out. These are my personal ideas and blog on stroke rehabilitation and stroke research. Do not attempt any of these without checking with your medical provider. Unless you join me in agitating, when you need these therapies they won't be there.

What this blog is for:

My blog is not to help survivors recover, it is to have the 10 million yearly stroke survivors light fires underneath their doctors, stroke hospitals and stroke researchers to get stroke solved. 100% recovery. The stroke medical world is completely failing at that goal, they don't even have it as a goal. Shortly after getting out of the hospital and getting NO information on the process or protocols of stroke rehabilitation and recovery I started searching on the internet and found that no other survivor received useful information. This is an attempt to cover all stroke rehabilitation information that should be readily available to survivors so they can talk with informed knowledge to their medical staff. It lays out what needs to be done to get stroke survivors closer to 100% recovery. It's quite disgusting that this information is not available from every stroke association and doctors group.

Wednesday, April 21, 2021

Abstract P194: Artificial Intelligence-Powered Non-Invasive and Frequency-Tuned Electromagnetic Field Therapy Improves Upper Extremity Motor Function in Sub-Acute Stroke Patients: A Pilot Randomized Controlled Trial

Well, they found something promising but didn't complete enough research to prove it out for sure or create protocols on it. Useless.

Abstract P194: Artificial Intelligence-Powered Non-Invasive and Frequency-Tuned Electromagnetic Field Therapy Improves Upper Extremity Motor Function in Sub-Acute Stroke Patients: A Pilot Randomized Controlled Trial

Originally published11 Mar 2021https://doi.org/10.1161/str.52.suppl_1.P194Stroke. 2021;52:AP194

Abstract

Background: Neural oscillations at specific frequencies have been associated with increased neuroplasticity. Additionally, exposure to extremely low frequency and low intensity electromagnetic fields (ELF-EMF) increases plasticity-related processes, with associated clinical improvements.

Aim: The purpose of this double-blind sham-controlled trial was to explore the benefit of BrainQ’s novel and non-invasive, artificial intelligence-powered, frequency-tuned ELF-EMF treatment (BQ) in improving upper extremity motor function (UEMF) in a sub-acute ischemic stroke population.

Methods: Study was planned for 50 subjects, but was discontinued due to COVID-19 at 25 subjects. Participants were randomized to receive 40 minutes of BQ treatment (active or sham) 5 days/week, for 8 weeks, in conjunction with 10 minutes of physical therapy. The BQ treatment uses artificial intelligence-based algorithms to extract motor-related spectral features in EEG for use as treatment frequencies. BQ treatment is delivered via a wearable device that transmits frequency-tuned ELF-EMF, facilitating neuroplasticity processes within the central nervous system. Primary endpoint: Fugl-Meyer Assessment - Upper Extremity (FMA-UE); Secondary endpoints: mRS, Action Research Arm Test (ARAT), Box and Block Test (BBT), NIHSS.

Results: FMA-UE scores improved significantly (and sooner) in the treatment group versus sham at week 4 (23.2±3.91 vs. 9.9±3.2; 13.6 points greater than sham p=0.0070) and after 8 weeks of treatment (31.5±2.97 vs. 23.1±4.99; p=0.0611). For mRS, at week 9 the treatment group showed a mean improvement of 2.5±0.18 points versus 1.3±0.16 points in the sham group (p=0.0005), i.e. a mean of 1.2 points higher than that of the sham group. Significant improvements were also observed in the ARAT-Pinch subscale (week 9: p=0.0082), BBT (week 6: p=0.0169; week 9: p<0.0001), and NIHSS (week 9: p=0.0340). No related adverse events were reported, supporting the safety of the treatment.

Conclusion: Our results show that BQ treatment significantly improves UEMF in a sub-acute ischemic stroke population across multiple clinical metrics. Further studies are planned and ongoing with larger study populations, and in related indications.